Health Care

Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%

Agilent Braces For Potential US-EU Tariff Hike, Maintains Annual Outlook

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

Agilent Braces For Potential US-EU Tariff Hike, Maintains Annual Outlook

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Elon Musk's Neuralink Hits $9 Billion Valuation With New Funding

Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty

Elon Musk's Neuralink Hits $9 Billion Valuation With New Funding

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

Why Is Teva Stock Trading Higher On Tuesday?

Health Care Recent News

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday?

Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.

FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sales and launch in the U.S. in June 2025.

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment remains on track across programs.

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

ORIC's Phase 1b trial of ORIC-944 in mCRPC shows PSA responses and strong tolerability, with Phase 3 trials and financing plans underway.

PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate

PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing correction and safety.

Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort

The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation introduces uncertainty into the nation's defense strategy against H5N1 avian influenza despite positive clinical trial results.

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

Ultragenyx sees rising revenue and analyst support as key drug launch approaches, with potential profitability projected for 2027.

Why These Healthcare Giants Could Face Pressure From Startups

The rise of new challengers is placing new pressure on publicly traded incumbents, which are deeply embedded in the traditional layers of healthcare.

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

Veru reports strong safety and efficacy for enobosarm added to semaglutide, showing reduced functional decline and muscle loss in older adults.

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK and Spero ended a Phase 3 trial early meeting efficacy goals in cUTIs, positioning its treatment as the first oral carbapenem in the U.S.

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

InflaRx ends its Phase 3 trial of vilobelimab in pyoderma gangrenosum and shifts focus to INF904 amid efforts to extend its cash runway.

With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around?

HC Wainwright upgrades Kyverna to Buy with a $5 target, citing upcoming trial data and a strong cash position that supports a runway into 2027.